ライフサイエンスコーパス: dimeglumine

1 er-17 and r = 0.80, P <.05 for gadopentetate dimeglumine).

2 r-17 and r = 0.75, P <.001 for gadopentetate dimeglumine).

3 red with that with 0.1 mmol/kg gadopentetate dimeglumine.

4 ntetate dimeglumine and 0.5 mol/L gadobenate dimeglumine.

5 before and after injection of gadopentetate dimeglumine.

6 dose (2 mL or 0.01 mmol/kg) of gadopentetate dimeglumine.

7 mote myocardium than that with gadopentetate dimeglumine.

8 ter a 30-40-minute infusion of gadopentetate dimeglumine.

9 nd after the administration of gadopentetate dimeglumine.

10 before and after injection of gadopentetate dimeglumine.

11 re obtained after injection of gadopentatate dimeglumine.

12 intravenous administration of gadopentetate dimeglumine.

13 istration of a single bolus of gadopentetate dimeglumine.

14 e and during administration of gadopentetate dimeglumine.

15 administration of 0.2 mmol/kg gadopentetate dimeglumine.

16 administration of 0.2 mmol/kg gadopentetate dimeglumine.

17 on of a 0.5-mL timing bolus of gadopentetate dimeglumine.

18 doses of 0.075 and 0.1 mmol/kg gadopentetate dimeglumine.

19 re and after administration of gadopentetate dimeglumine.

20 during infusion of 0.2 mmol/kg gadopentetate dimeglumine.

21 hases with saline and 2 mmol/L gadopentetate dimeglumine.

22 ht joints), after injection of gadopentetate dimeglumine.

23 administration of 0.1 mmol/kg gadopentetate dimeglumine.

24 e disodium and 204 performed with gadobenate dimeglumine.

25 imeglumine was substituted for gadopentetate dimeglumine.

26 al baseline reaction rate with gadopentetate dimeglumine.

27 lergic-like reactions than was gadopentetate dimeglumine.

28 more often than with intravenous gadobenate dimeglumine.

29 material-enhanced imaging with gadopentetate dimeglumine.

30 the kinetics of di-tyrosine of gadopentetate dimeglumine.

31 ng intravenous administration of gadopentate dimeglumine.

32 ynamic injection of 8-10 mL of gadopentetate dimeglumine.

33 and mean transit time (MTT) of gadopentetate dimeglumine.

34 intravenous bolus injection of gadopentetate dimeglumine.

35 a dual-bolus administration of gadopentetate dimeglumine (0.0025 mmol/kg followed by 0.10 mmol/kg).

36 re and after administration of gadopentetate dimeglumine (0.1 mmol per kilogram of body weight).

37 n = 1; 16 mL, n = 1] and 99 with gadobenate dimeglumine [0.1 mmol per kilogram of body weight, maxim

38 fic (di-5-hydroxytryptamide of gadopentetate dimeglumine, 0.1 mmol per kilogram of bodyweight) or a n

39 n-MPO-specific (di-tyrosine of gadopentetate dimeglumine, 0.1 mmol/kg) contrast agent, animals underw

40 re randomized to 1 of 3 doses of gadopentate dimeglumine: 0.05, 0.10, or 0.15 mmol/kg.

41 All animals received gadopentetate dimeglumine 1 hour after reperfusion and underwent imagi

42 ith gadoxetate disodium than with gadobenate dimeglumine (10.7% [37 of 345 examinations] vs 0.5% [one

43 tate disodium administration than gadobenate dimeglumine (14% [14 of 99] vs 5% [five of 99], P = .05)

44 ium, 16.6 mL vs 16.6 mL, P = .99; gadobenate dimeglumine, 18.0 mL vs 17.8 mL, P = .77) and mean time

45 dolinium-based contrast media (gadopentetate dimeglumine, 31 540; gadobenate dimeglumine, 66 152; oth

46 on-related artifact compared with gadobenate dimeglumine (39% vs 10%, P < .0001) and of new severe tr

47 adopentetate dimeglumine, 31 540; gadobenate dimeglumine, 66 152; other, 7915).

48 imeglumine was substituted for gadopentetate dimeglumine, a significant transient increase occurred i

49 mmol per kilogram of body weight gadobenate dimeglumine administered at a rate of 2.0 mL per second)

50 F) MR imaging before and after gadopentetate dimeglumine administration.

51 tive patients before and after gadopentetate dimeglumine administration.

52 nt are affected by the rate of gadopentetate dimeglumine administration.

53 different IRE parameters after gadopentetate dimeglumine administration.

54 loped NSF after administration of gadobenate dimeglumine after more than 2 years' mean follow-up.

55 Liposomes encapsulating gadopentetate dimeglumine, an MR-detectable model representing pharmac

56 myocardium (0.23 +/- 0.02 for gadopentetate dimeglumine and 0.16 +/- 0.01 for 99mTc-DTPA).

57 am of body weight of 0.5 mol/L gadopentetate dimeglumine and 0.5 mol/L gadobenate dimeglumine.

58 myocardium (0.90 +/- 0.05 for gadopentetate dimeglumine and 0.89 +/- 0.04 for 99mTc-DTPA) than in no

59 tional distribution volumes of gadopentetate dimeglumine and 99mTc-DTPA are similar and indicate extr

60 o 10, 30, and 50 minutes after gadopentetate dimeglumine and both gadomer-17 injections, respectively

61 ning rat was administered both gadopentetate dimeglumine and cationized ferritin to visualize the int

62 Gadobenate dimeglumine and gadopentetate dimeglumine were the agent

63 ng the switch from gadodiamide to gadobenate dimeglumine and gadopentetate dimeglumine, and the adopt

64 istration of mesoporphyrin and gadopentetate dimeglumine and histochemical staining, the function and

65 eline in NASH mice imaged with gadopentetate dimeglumine and in MPO knockout NASH mice with MPO-Gd, w

66 ed intraarticular injection of gadopentetate dimeglumine and normal saline in a ratio of 1:200.

67 nce of 3.1 msec was noted between gadobenate dimeglumine and placebo (95% CI: -1.8, 8.0) after indivi

68 Gadobenate dimeglumine and saline placebo were injected intravenous

69 lationship between the dose of gadopentetate dimeglumine and the time to onset of NSF.

70 fact was threefold dilution of gadopentetate dimeglumine and use of a short echo time (1 msec).

71 er-17 and r = 0.60, P =.05 for gadopentetate dimeglumine) and with areas of reduced MBF (r = 0.70, P

72 oved Gd chelate, Multihance((R)) (gadobenate dimeglumine), and a novel experimental liposomal Gd agen

73 (gadodiamide, gadoversetamide, gadopentetate dimeglumine, and gadobenate dimeglumine) produced a maxi

74 gents (gadopentetate dimeglumine, gadobenate dimeglumine, and gadofosveset trisodium) diluted in eith

75 general enhancement seen with gadopentetate dimeglumine, and reflux from the duodenum could not acco

76 to gadobenate dimeglumine and gadopentetate dimeglumine, and the adoption of restrictive GBCA polici

77 intravenous administration of gadopentetate dimeglumine, and these data were used to calculate EF.

78 rs, the other 16 rats received gadopentetate dimeglumine at 24 hours, and all animals underwent imagi

79 Therefore, half-dose gadobenate dimeglumine at 3-T MR imaging may be sufficient for asse

80 dimeglumine, gadodiamide, and gadopentetate dimeglumine at a concentration of 0.1 mmol/L and by gado

81 ed after the administration of gadopentetate dimeglumine at a concentration of 25% with fast SPGR (6/

82 glumine compared with that for gadopentetate dimeglumine at all time points from 3 minutes after inje

83 (P <.05) higher than that with gadopentetate dimeglumine at first-pass imaging.

84 tients after administration of gadopentetate dimeglumine (average dose, 0.11 mmol/kg).

85 application of the linear GBCA gadopentetate dimeglumine but not by the macrocyclic GBCA gadoterate m

86 administration of 0.1 mmol/kg gadopentetate dimeglumine by means of bolus (10-second) injection (n =

87 was filled with a solution of gadopentetate dimeglumine, catheter movement was always depicted.

88 nd vasculitis mice imaged with gadopentetate dimeglumine (CNR = 10.6) (P < .05).

89 ificantly worse than those in the gadobenate dimeglumine cohort (P < .005).

90 (P <.05) superior enhancement for gadobenate dimeglumine compared with that for gadopentetate dimeglu

91 ors was achieved with 0.1 mmol/kg gadobenate dimeglumine compared with that with 0.1 mmol/kg gadopent

92 the linear agents gadodiamide and gadobenate dimeglumine compared with the macrocyclic agents gadobut

93 normalized to pectoral muscle gadopentetate dimeglumine concentration in invasive cancers was also c

94 The T1 values, change in gadopentetate dimeglumine concentration, and extraction-flow products

95 atients with prior exposure to gadopentetate dimeglumine contrast during imaging studies.

96 Gadopentetate dimeglumine did not produce selective enhancement of the

97 yed by using mesoporphyrin and gadopentetate dimeglumine differed from each other.

98 Gadopentetate dimeglumine diluted 1:1 with 0.9% normal saline was used

99 Gadobenate dimeglumine dose was weight based (0.1 mmol per kilogram

100 ed higher cumulative and total gadopentetate dimeglumine doses had a higher risk of developing NSF th

101 se (approximately 0.1 mmol/kg) gadopentetate dimeglumine during a three-station, dual-injection exami

102 Hyperintensity from gadopentetate dimeglumine enabled visualization of renal tubules, and

103 TOF sequences with or without gadopentetate dimeglumine enables accurate identification of the proxi

104 Ninety patients underwent gadobenate dimeglumine-enhanced abdominal magnetic resonance (MR) f

105 44,224 patients who underwent gadopentetate dimeglumine-enhanced MR examinations.

106 2 included patients who underwent gadobenate dimeglumine-enhanced MR imaging.

107 -saturated T1-weighted dynamic gadopentetate dimeglumine-enhanced sequences also were performed.

108 ide-enhanced studies but not with gadobenate dimeglumine-enhanced studies, likely reflecting differen

109 d between half-dose and full-dose gadobenate dimeglumine-enhanced synovial tissue (mean: 914.35 +/- 2

110 sms, di-5-hydroxytryptamide of gadopentetate dimeglumine exhibited delayed washout kinetics compared

111 within 3 months after the last gadopentetate dimeglumine exposure (range, 1-59 months) in 21 (66%) of

112 records were then reviewed for gadopentetate dimeglumine exposure, renal status, concomitant diseases

113 d pre- and postcontrast (20 mL gadopentetate dimeglumine) fat-saturated 2D GRE breath-hold imaging an

114 d well with those observed for gadopentetate dimeglumine (Fe-tCDTA Pearson R, 0.99; P = .0003; Fe-DTP

115 veric knees, with placement of gadopentetate dimeglumine-filled tubes along their course and tibial i

116 ed to receive either MPO-Gd or gadopentetate dimeglumine first.

117 for gadoxetate disodium than for gadobenate dimeglumine for both the general population (17% [17 of

118 tent CNR improvements than did gadopentetate dimeglumine; further evaluation of its utility for coron

119 ee gadolinium contrast agents (gadopentetate dimeglumine, gadobenate dimeglumine, and gadofosveset tr

120 as stimulated by gadoversetamide, gadobenate dimeglumine, gadodiamide, and gadopentetate dimeglumine

121 iaminetriacetate (Mn-PyC3A) to gadopentetate dimeglumine (Gd-DTPA) and to evaluate the excretion, pha

122 The use of gadopentetate dimeglumine (Gd-DTPA) as a contrast agent showed smaller

123 Gadopentetate dimeglumine (Gd-DTPA) dynamic magnetic resonance imaging

124 ration of the MRI contrast agent gadopentate dimeglumine [Gd-DTPA(2-)]) is used as an index of the mo

125 rformed with 5 mL of undiluted gadopentetate dimeglumine hand injected into each renal artery (total

126 Injection of 0.2 mmol/kg gadobenate dimeglumine has no detrimental effect on cardiac electro

127 The use of gadopentetate dimeglumine improved delineation of soft-tissue inflamma

128 intrathecal administration of gadopentetate dimeglumine in 15 patients clinically suspected of havin

129 maging and/or MR angiography with gabobenate dimeglumine in 2010.

130 l impairment after exposure to gadopentetate dimeglumine in a dose- and time-dependent manner.

131 amide and one had been exposed to gadobenate dimeglumine in addition to gadodiamide.

132 es were compared with those of gadopentetate dimeglumine in blood serum phantoms at 1.5 T, 3 T, and 7

133 Normal-saline bags containing gadopentetate dimeglumine in concentrations of 0-20 mmol/L were imaged

134 uired during the first pass of gadopentetate dimeglumine in coronary arteries and up to 6 and 10 minu

135 gnificantly more often than after gadobenate dimeglumine in patients who received both contrast media

136 ficantly longer than those for gadopentetate dimeglumine in regions of postinfarction scarring (mean,

137 the application of 0.2 mmol/kg gadopentetate dimeglumine in the interventricular septum, left ventric

138 igher for gadoteridol than for gadopentetate dimeglumine in the physis, epiphyseal cartilage, and sec

139 Inclusion of phantoms of gadopentetate dimeglumine in tubes allowed estimation of intravascular

140 m of tissue (95% CI: 3.5, 6.1) in gadobenate dimeglumine-injected rats, and 6.9 mug gadolinium per gr

141 minimally efficacious dose of gadopentetate dimeglumine injection (Magnevist Injection; Berlex Labor

142 seven of 47 (15%) subjects after gadobenate dimeglumine injection and in five of 47 (11%) subjects a

143 ent IRE ablation without prior gadopentetate dimeglumine injection to serve as control animals.

144 lse sequences before and after gadopentetate dimeglumine injection.

145 t on the images obtained after gadopentetate dimeglumine injection.

146 nsional gradient-echo MR after gadopentetate dimeglumine injection.

147 ts (nine who had received GBCA gadopentetate dimeglumine injections previously [one to eight times] a

148 onic contrast agent; n = 6) or gadopentetate dimeglumine (ionic contrast agent; n = 6).

149 Gadopentetate dimeglumine is an alternative radiographic contrast mate

150 A low dose of 0.05 mmol/kg gadopentetate dimeglumine is at least as efficacious as higher doses.

151 y with intranodal injection of gadopentetate dimeglumine is feasible, produces good images of the cen

152 Gadopentetate dimeglumine is of limited use.

153 contrast-enhancing lesions on gadopentetate dimeglumine magnetic resonance images after treatment wi

154 the 2nd year after it replaced gadopentetate dimeglumine (maximum per quarter, 0.10% [four of 4122];

155 Gadobenate dimeglumine may be safe in this population.

156 emarcated by mesoporphyrin and gadopentetate dimeglumine may provide an estimation of potentially sal

157 on imaging with Gadomer-17 and gadopentetate dimeglumine, microsphere blood flow (MBF) testing, and t

158 ected contrast agent solution (gadopentetate dimeglumine mixed with trypan blue dye) in and around th

159 traarticular administration of gadopentetate dimeglumine (MR arthrography).

160 23), referred to as MPO-Gd, or gadopentetate dimeglumine (n = 10).

161 nd verified qualitatively with gadopentetate dimeglumine on both perfusion and BOLD images obtained a

162 maging in the same tumors with gadopentetate dimeglumine on day 2.

163 ntravenous injection of either gadopentetate dimeglumine or EP-3533.

164 intravenous bolus injection of gadopentetate dimeglumine or gadoteridol (0.1 mmol/kg), nine images we

165 e use of either a linear GBCA (gadopentetate dimeglumine) or a macrocyclic GBCA (gadoterate meglumine

166 gnificant (P <.05) preference for gadobenate dimeglumine over gadopentetate dimeglumine was noted bot

167 The reaction rate for gadobenate dimeglumine peaked (maximum per quarter, 0.38% [16 of 42

168 three injections: 0.20 mmol of gadopentetate dimeglumine per kilogram of body weight and 0.05 and 0.1

169 tion of a bolus of 0.1 mmol of gadopentetate dimeglumine per kilogram of body weight.

170 administration of 0.2 mmol of gadopentetate dimeglumine per kilogram of body weight.

171 ed after injection of 0.1 mmol gadopentetate dimeglumine per kilogram of body weight.

172 -83 years) had been exposed to gadopentetate dimeglumine prior to NSF onset.

173 e, gadopentetate dimeglumine, and gadobenate dimeglumine) produced a maximum stimulation of fibroblas

174 Extracellular gadopentetate dimeglumine provided excellent infarct detection but a s

175 55 seconds after injection of gadopentetate dimeglumine (PSIC, 36% +/- 24 vs 56% +/- 27, respectivel

176 32, respectively; P <.001) and gadopentetate dimeglumine (PSIC, 49% +/- 31 vs 81% +/- 43, respectivel

177 tively, compared with those of gadopentetate dimeglumine (r1 = 4.1 mmol(-1) .

178 The final gadobenate dimeglumine reaction rate (last 3 quarters, 0.12% [17 of

179 isibility of the physis, while gadopentetate dimeglumine resulted in greater contrast between the phy

180 with di-5-hydroxytryptamide of gadopentetate dimeglumine revealed a difference in enhancement ratio b

181 ed intraarticular injection of gadopentetate dimeglumine, ropivacaine 0.5%, and normal saline in a ra

182 ilable catheters filled with a gadopentetate dimeglumine solution and a fast, two-dimensional, time-r

183 patients by using a first-pass gadopentetate dimeglumine T2*-weighted echo-planar perfusion sequence

184 se rats, two were administered gadopentetate dimeglumine to visualize renal tubules on T1-weighted gr

185 ise quantitative estimation of gadopentetate dimeglumine uptake in breast tumors, which helps improve

186 olinium deposition in the DN with gadobenate dimeglumine use, although it is considerably less than t

187 n exposed to median cumulative gadopentetate dimeglumine volumes of 35, 40, 85, and 117.5 mL over the

188 nal artery stenosis, undiluted gadopentetate dimeglumine was administered in an aortic bolus to provi

189 Gadobenate dimeglumine was associated with significantly more overa

190 Renal extraction fraction of gadopentetate dimeglumine was determined with T1 measurements of flowi

191 hic attenuation of the diluted gadopentetate dimeglumine was equivalent to diatrizoate meglumine dilu

192 n the timing examination, 1 mL gadopentetate dimeglumine was followed with 15 mL saline, both at 2 mL

193 re, a single dose of 0.5 mL of gadopentetate dimeglumine was injected into the lumbar subarachnoid sp

194 For comparison, gadopentetate dimeglumine was injected into three other swine at a dos

195 or gadobenate dimeglumine over gadopentetate dimeglumine was noted both off-site and on-site for the

196 Similar preference for gadobenate dimeglumine was noted by off-site readers and on-site in

197 quence after administration of gadopentetate dimeglumine was obtained.

198 traarticular administration of gadopentetate dimeglumine was performed in 10 adult cadaveric glenohum

199 Gadopentetate dimeglumine was peripherally injected at rest and during

200 site investigators, respectively, gadobenate dimeglumine was preferred in 13, 17, and 16 patients; ga

201 ed in 13, 17, and 16 patients; gadopentetate dimeglumine was preferred in four, four, and four patien

202 years before and 3.5 years after gadobenate dimeglumine was substituted for gadopentetate dimeglumin

203 After gadobenate dimeglumine was substituted for gadopentetate dimeglumin

204 graphy performed with 30 mL of gadopentetate dimeglumine was the reference standard.

205 ory University (center B), and gadopentetate dimeglumine was used at Wake Forest University (center C

206 than at the two centers where gadopentetate dimeglumine was used.

207 l injections of small doses of gadopentetate dimeglumine were combined with a fast spoiled-gradient-e

208 sed contrast agents other than gadopentetate dimeglumine were excluded.

209 te after the administration of gadopentetate dimeglumine were retrospectively evaluated for perilesio

210 Gadobenate dimeglumine and gadopentetate dimeglumine were the agents used in the postadoption per

211 who underwent MR imaging with gadopentetate dimeglumine) were identified.

212 gent di-5-hydroxytryptamide of gadopentetate dimeglumine, which is a paramagnetic MPO substrate that

213 travenous injection of 2 mL of gadopentetate dimeglumine, which was repeated following intravenous in

214 ically after administration of gadopentetate dimeglumine, with the first enhanced acquisition timed f